Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients

KOL Event will be held Thursday, November 11th at 11:30 a.m. ET

CRANFORD, N.J., Oct. 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will host a key opinion leader (KOL) webinar on the compelling need to salvage central venous catheters in patients with central line associated blood stream infections (CLABSI) on Thursday, November 11, 2021 at 11:30am Eastern Time.

The webinar will feature a presentation by leading infectious disease experts Issam Raad, MD, University of Texas MD Anderson Cancer Center and Mark Rupp, MD, University of Nebraska Medical Center. Dr. Raad will discuss the unmet medical need in the treatment of patients with infected central venous catheters (CVCs), and the potential of Citius's Mino-Lok® treatment to salvage infected catheters. Dr. Rupp will discuss the effect of the COVID-19 Pandemic on CLABSI rates in acute care facilities. Citius Pharmaceuticals' Chief Medical Officer, Myron Czuczman, MD, will provide an update on the company's Mino-Lok® program.  Drs. Raad, Rupp and Czuczman will be available to answer questions following the formal presentations.

Pre-registration for the webcast is required.


Thursday, November 11, 2021


11:30 a.m. ET

Registration link

To participate, please register prior to the event date using this link

Webcast (live and archive)

Available at in the "Events" section


Questions may be submitted in advance using this link

Featured Speakers


Dr. Issam Raad, G. H. Fletcher Distinguished Chair & Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, is considered one of the leading experts in the field of health care related infections and infections in cancer on a worldwide basis. During his more than 25 years at MD Anderson, Dr. Raad has made numerous outstanding clinical research contributions that have led to significant improvements in controlling life-threatening infections for patients with cancer and other serious illnesses throughout the world. His research includes development of innovative antimicrobial central venous catheters and devices that have reduced the risk of bloodstream infections worldwide more than 12-fold. In the most recent CDC Guidelines (2011), his innovations, including the antimicrobial catheters and maximal sterile barrier, have been recommended at the highest level (Category 1A) for the prevention of health care associated bloodstream infections which have become the standard of care.

Mark Rupp, MD

Dr. Mark Rupp, is Chief of the Division of Infectious Diseases and Professor in the Department of Internal Medicine, Section of Infectious Diseases at the University of Nebraska Medical Center. He is the Medical Director of The Nebraska Medical Center Department of Healthcare Epidemiology and Co-Director of the Antimicrobial Stewardship Program. He is a Diplomate, American Board of Internal Medicine, and in the subspecialty area of Infectious Diseases. Dr. Rupp is also a Fellow of the Society for Hospital Epidemiology of America (SHEA), American College of Physicians (ACP), and the Infectious Diseases Society of America (IDSA). He is a Past-President of SHEA and is a past-president of ASM Division L (Infection Control/Hospital Epidemiology). Dr. Rupp has served as a consultant for the US Food and Drug Administration as well as the Centers for Disease Control and Prevention. 

Myron Czuczman, MD, Citius Pharmaceuticals Chief Medical Officer

Dr. Czuczman is an experienced physician-scientist, academic oncologist, and pharmaceutical executive with decades of experience in strategic design, implementation, and oversight for the global development of novel therapeutics for hematologic malignancies. Dr. Czuczman joined Citius from Celgene where he was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL. In this role, Dr. Czuczman managed a global team of physicians and scientists responsible for cross-functional development of compounds from proof-of-principle to worldwide registration. Prior to his career in pharma, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI-designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Roswell Park Comprehensive Cancer Center.

Dr. Czuczman received his medical degree from Pennsylvania State University College of Medicine after graduating magna cum laude in biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center in New York City.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial.  Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19.  For more information, please visit

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including those from existing and new pipeline assets; uncertainties relating to preclinical and clinical testing; our need for substantial additional funds; the early stage of products under development; our dependence on third-party suppliers; our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our ability to commercialize our products if approved by the FDA; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our ability to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website at, including in our Annual Report on Form 10-K for the year ended September 30, 2020, filed with the SEC on December 16, 2020 and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Relations for Citius Pharmaceuticals:

Ilanit Allen
Vice President, Investor Relations and Corporate Communications
T: 908-967-6677 x113

Cision View original content to download multimedia:

SOURCE Citius Pharmaceuticals, Inc.